Quick Facts

• Nasal Congestion: Helps to temporarily relieve a stuffy nose and sinus pressure.
• Runny Nose & Sneezing: May support the reduction of excessive nasal discharge and sneezing.
• Minor Discomfort: Can be used to address minor aches, pains, or headache associated with cold symptoms.
• Fever: Used for the temporary reduction of fever.

---

Риностоп is a combination medication indicated for the temporary relief of a range of symptoms associated with the common cold and flu. It is used as a component of symptom management to help individuals feel more comfortable while the body addresses the underlying viral illness.

This medication is primarily used to help manage nasal congestion and sinus pressure, which often occur due to the common cold or respiratory allergies. It provides support for the temporary relief of a stuffy nose, facilitating improved nasal airflow.

Additionally, the formulation is intended to support the reduction of common cold symptoms such as a runny nose and sneezing. It may also be used to address minor symptoms of discomfort, including headache, mild muscle aches, and the temporary reduction of fever that may accompany these conditions.

Patients should consult a healthcare provider to determine if this therapy is appropriate for their specific needs.

Regulatory References

1. NIH MedlinePlus guidance

This medicine, which contains Xylometazoline, is not suitable for everyone and its use is strictly defined by regulatory guidelines based on age, concurrent medication, and certain pre-existing health conditions.

---

Official Contraindications

Use is contraindicated (prohibited) for individuals with the following conditions or situations:

• Hypersensitivity to Xylometazoline or any other ingredient.
• Narrow-angle glaucoma.
• Chronic nasal inflammation with dryness (rhinitis sicca) or atrophic rhinitis.
• Recent neurosurgery (e.g., trans-sphenoidal hypophysectomy or surgery exposing the dura mater).
• Phaeochromocytoma (adrenal gland tumor).
• Current or recent use (within the last two weeks) of Monoamine Oxidase Inhibitors (MAOIs), due to the risk of hypertensive crisis.

---

Age and Concentration Restrictions

Eligibility is tied to the specific concentration used:

• The 0.1% concentration is typically contraindicated in children under 12 years of age.
• The 0.05% concentration is contraindicated in children under 2 years of age (or under 6 years, depending on the specific national label).

---

Use Requiring Caution

Special medical consultation and caution are required for patients with:

• Cardiovascular disease (e.g., hypertension, Long QT syndrome, severe atherosclerosis).
• Metabolic conditions (e.g., hyperthyroidism, diabetes mellitus).
• Prostatic hypertrophy (enlarged prostate).

---

Pregnancy and Lactation

Use during pregnancy is generally advised against as a precaution due to the potential for systemic vasoconstrictor effects. Use during lactation should be done only after consulting a doctor, as it is unknown whether the active substance is excreted in breast milk.

Риностоп, which contains the active substance Xylometazoline Hydrochloride, is documented to have pharmacodynamic interactions with specific classes of medicines. These interactions arise from the intensification of the sympathomimetic effects associated with Xylometazoline, primarily leading to the risk of significant blood pressure elevation.

Interacting Substance Categories	Official Regulatory Classification	Interaction Outcome Focus
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated Combination	Hypertensive Crisis Risk
Tricyclic and Tetracyclic Antidepressants	Use Restricted / Not Recommended	Elevated Blood Pressure

The most critical restriction is the formal Contraindication with Monoamine Oxidase Inhibitors. This prohibition is enforced to prevent the potentiation of sympathomimetic effects that can result in a hypertensive crisis. Accordingly, Xylometazoline must not be administered concurrently with any MAOI, nor should it be used within 14 days after discontinuing MAOI treatment.

Regulatory documentation further notes that the concurrent use of Xylometazoline with Tricyclic and Tetracyclic Antidepressants is restricted due to the potential for the same sympathomimetic intensification, posing a risk of elevated blood pressure. Caution is also advised when co-administering Xylometazoline with other Sympathomimetic Agents, as the additive pharmacodynamic effects may increase blood pressure. No specific pharmacokinetic (CYP- or transporter-mediated) interactions are documented in the official regulatory information.

The action of the active ingredient, Xylometazoline, is based on a localized pharmacological mechanism that directly influences the blood vessels lining the nasal passages. This process involves precise engagement with the sympathetic nervous system to alter tissue volume.

Alpha-Adrenergic Receptor Agonism

Xylometazoline acts as a direct-acting agonist that selectively targets the alpha-adrenergic (alpha-adrenoceptors) on the vascular smooth muscle cells. This action mimics sympathetic signaling, initiating a cascade that leads to the contraction of these muscle cells and influences the vascular tone pathway.

Localized Vasoconstriction and Tissue Shrinkage

Agonism triggers vasoconstriction—a physical narrowing of the arterioles and venous sinuses within the nasal lining—by promoting Ca^2+-dependent smooth muscle contraction. The resulting reduction in blood flow and local blood volume causes the swollen nasal mucosa to mechanically shrink, which physiologically opens the obstructed nasal passages.

Constraints: Receptor Desensitization

The efficacy of this vasoconstrictive mechanism can decrease with prolonged or excessive use due to the dynamic process of receptor desensitization ( extittachyphylaxis). Furthermore, the chronic stimulation can ultimately lead to a compensatory rebound vasodilation and edema once the drug's effect subsides, a key constraint characterized by exaggerated rebound vasodilation.

Administration Guidelines

The following instructions detail the proper administration of Риностоп Syrup (Rhinostop Syrup) according to the product's standardized administration protocol. These guidelines describe the steps for correct usage.

---

Dosing Schedule and Administration Route

The route of administration for this formulation is oral, using a measuring spoon for precise dosing. The drug is taken at a consistent frequency across all specified age groups.

Age Group	Single Dose Volume	Frequency
Children 6–12 years	5 ml (1 measuring spoon)	Every 6 hours
Adults & Children > 12 years	15 ml (3 measuring spoons)	Every 6 hours

---

Special Conditions

Timing in Relation to Meals: There is no documented requirement to take the syrup with or without food. The focus is on maintaining the every 6 hours frequency.

Preparation Requirements: The syrup is administered directly and does not require dilution or reconstitution prior to use.

Missed-Dose Rules: Regarding a missed dose, the protocol is to resume the regular 6-hour dosing schedule as soon as the missed dose is noted.

---

Procedural Structure

The use protocol focuses on measurement and ingestion:

1. Measure the appropriate volume (5 ml or 15 ml) using the provided measuring spoon or device, as determined by the patient's age group.
2. Administer the dose orally.
3. Repeat the dosage administration every 6 hours to maintain the necessary concentration.

This structure outlines a fixed-schedule protocol intended for standard, short-term use, emphasizing time-based regularity over situational timing factors.

Research Evidence / Overview of Studies for Риностоп

Evidence for Use in Acute Nasal Congestion (Common Cold)

This section will summarize the body of evidence—primarily short-term Randomized Controlled Trials (RCTs)—that examined the effects of Xylometazoline on objective measures of nasal airflow and subjective reports of a blocked nose during the common cold. The active ingredient was studied in research contexts involving conditions associated with acute or disruptive episodes, such as the common cold. Research has explored short-term symptom changes in adults with noticeable nasal congestion. Studies used objective measurements of nasal airflow and subjective measurements from patients to understand symptom patterns. Findings describe patterns observed in the studies as measured by objective readings.

Outcomes Evaluated in Decongestion Studies

This sub-section will detail the specific measures used in trials, including the assessment of time to relief, overall symptom severity scores, and patient-reported measures of quality of life like sleep and general well-being. Researchers examined outcomes describing episodic or acute changes and patient-reported outcomes describing perceived discomfort. Trials assessed outcomes reflecting daily functioning, such as vitality and physical activity level, applied in studies examining patient-reported experiences. Data show patterns related to how quickly individuals in the study reported changes and how symptoms evolved in the observed populations. Research highlights changes measured during the study period, including patient reports of outcomes such as sleep quality.

Evidence for Use in Congestion Associated with Allergic Rhinitis

This section will outline the structure of studies that have investigated the use of Xylometazoline for relieving nasal congestion arising from allergic rhinitis, noting the frequent focus on combination therapies in this clinical context. Xylometazoline was studied for conditions characterized by fluctuating or episodic manifestations, such as allergic rhinitis, where symptoms may vary in intensity. Research examined the use of the medicine, often in combination with other substances, in conditions involving periods of heightened symptoms. Studies monitored outcomes related to physical discomfort, specifically using symptom scales to track changes. Research provides insight into short-term changes in reported symptom intensity in the observed studies.

---

Long-Term Studies and Follow-Up Duration

This section will summarize the available data regarding the typical observation periods in clinical trials (which are generally short-term) and describe what the research indicates regarding the use of the medicine for periods extending beyond seven days. The follow-up durations for efficacy studies were limited, as trials often focus on short-term symptom patterns over defined time intervals. Research describing the patterns of use over an extended period (more than seven days) is less common, and information for long-term outcomes is limited. While some studies observed responses in healthy subjects for periods up to several weeks, there is limited information for long-term outcomes in patient populations with recurring or chronic conditions.

---

Evidence in Specific Patient Populations

This section will describe which patient groups—such as children and older adults—have been included in the research base and will note which populations have limited or specialized evidence available. Studies have explored the use of the active substance in children, often featuring distinct formulations and concentrations for this group. The evidence base primarily focuses on adults, meaning data for certain groups, such as the older adult population or those with specific comorbidities, remains insufficient. Research is ongoing to examine how symptoms evolve in diverse populations, but subgroup findings are uncertain due to modest sample sizes and follow-up durations.

---

What Remains Uncertain in the Research

This final section will synthesize the main evidence gaps and limitations as documented in authoritative scientific sources, highlighting areas where research is still considered insufficient, such as the full long-term physiological impact or a dedicated body of research for certain chronic conditions. Research highlights that comparative evidence is lacking in some areas, and the results apply only to the specific populations studied. Findings help contextualize how patients reported their experience in a controlled setting, but comparative data against newer standards of care is limited. The evidence contributes to the broader evidence landscape, and the short-term evidence base was evaluated by sources as being formally graded as High.

Key Studies & References

1. The efficacy of xylometazoline, the risk of rhinitis medicamentosa (RM), and treatment strategies: A review of published studies
2. Public Assessment Reports of the Medicines Evaluation Board in the Netherlands Nasadur 1 mg/ml and 0.5 mg/ml nasal spray, solution
3. Over-the-counter (OTC) medicine monograph: topical nasal decongestants (TGA)

Common questions about Риностоп (FAQ)

Q: Does Rinostop contain hormones?

No, according to official product information, the active substance, Xylometazoline, is not a hormone or a corticosteroid. It is classified as a sympathomimetic agent. This means it works by stimulating nerve receptors that cause localized blood vessels to narrow, which provides relief from nasal congestion.

Q: Can Rinostop be used if I have chronic sinusitis?

Official therapeutic indications state that Rinostop is approved for the symptomatic relief of nasal congestion associated with sinusitis. However, the medicine is generally intended for short-term use. Consultation with a healthcare professional may be necessary for comprehensive treatment guidance regarding chronic conditions.

Q: Are there studies confirming the effectiveness of Rinostop?

Yes, studies and official regulatory documentation indicate that Xylometazoline is an effective decongestant. Its ability to relieve nasal congestion has been demonstrated in clinical trials, demonstrating its ability to relieve nasal congestion when compared to placebo.

Q: What is the difference between Rinostop in spray form and drops?

Official regulatory documents confirm that Rinostop is available in both spray and drop formulations. These differences typically relate to the method of application (delivery device) and may involve variations in the inactive ingredients (excipients) used, such as preservatives or moisturizing components.

Q: What is known about the use of Rinostop in the elderly?

According to official dosing recommendations, the dosage for the elderly is generally the same as the recommended adult dose. As with all sympathomimetic drugs, caution should be exercised, and usage should be kept within the short duration specified on the label.

Q: How often do serious side effects from Rinostop occur?

Official product documentation categorizes side effects by frequency (e.g., Common, Uncommon, Rare, Very Rare). Serious systemic side effects, such as heart palpitations, elevated blood pressure (hypertension), and irregular heartbeat (arrhythmia), are typically classified as Rare or Very Rare.

Q: What is the role of Rinostop in treating a cold in general?

The role of Rinostop is focused on providing temporary symptomatic relief from nasal congestion caused by the common cold. Its active substance, Xylometazoline, works by its vasoconstrictive action, which helps shrink swollen tissues in the nasal passages to allow for clearer breathing.

Q: What should I do if Rinostop doesn't help after several days of use?

The official product information advises consulting a healthcare professional if your symptoms do not improve, or if they worsen after 7 days of use. This is an important instruction, as prolonged congestion may signal a different underlying condition.

Q: Is Rinostop officially approved for the treatment of all types of rhinitis?

No, the therapeutic indications are specific. Rinostop is officially approved for the symptomatic relief of nasal congestion associated with seasonal allergic rhinitis (like hay fever) and perennial (year-round) allergic rhinitis, as well as sinusitis.

Q: Can Rinostop affect the ability to drive?

Regulatory information states that Xylometazoline has a negligible or no influence on the ability to drive and operate machinery. However, if you experience rare side effects like headache or visual disturbances, caution may be warranted.

Q: Should I rinse my nose before using Rinostop?

The official instructions for use generally recommend gently clearing the nose, such as by blowing it, before applying the nasal spray or drops. This may help ensure the medicine can make effective contact with the nasal mucosa.

Q: Is there a difference in composition between different versions of Rinostop?

Yes, while the active ingredient (Xylometazoline) remains the same, the list of inactive ingredients (excipients) can differ between specific versions of the product. For instance, some formulations may contain certain preservatives, while others may include moisturizing agents like Hypromellose.

Q: If I use Rinostop, can I take painkillers?

Official regulatory documents do not list direct interactions between Xylometazoline and most common over-the-counter painkillers. However, caution is advised regarding co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) if the user has pre-existing high blood pressure (hypertension).

Q: Can Rinostop cause a dry throat?

Yes, according to the official safety documentation, temporary irritation symptoms are common. This can include a mild stinging or dryness sensation in the tissues of the nasal mucosa and/or the throat immediately following application.

Q: What official warnings and precautions exist for Rinostop?

Regulatory documents contain special warnings regarding use. Caution is required for patients with pre-existing conditions such as hypertension, heart disease, diabetes mellitus, or hyperthyroidism. The product information indicates that use beyond seven consecutive days should be avoided.

Q: Why might doctors recommend limiting the use of Rinostop?

The primary regulatory reason for limiting use is to prevent a known safety concern called rebound congestion (rhinitis medicamentosa). Official sources warn that prolonged or excessive use can lead to secondary nasal congestion or atrophy (damage) of the nasal lining.

Q: What volume of active substance is contained in one dose of Rinostop?

Official product labeling specifies the amount of active substance in each metered dose (e.g., one spray). This amount is typically provided in micrograms (mcg) and depends directly on the concentration of the formulation, such as the 0.05% or 0.1% versions.

Q: What is considered an overdose of Rinostop, and what are the general signs?

Official product documentation details signs of overdose, which can include severe dizziness, sweating, slowed heart rate (bradycardia), changes in blood pressure, headache, and reduced body temperature. In very serious cases, respiratory depression or seizures may occur.

How to Store and Dispose of Риностоп?

The storage and disposal of Риностоп (Xylometazoline Hydrochloride) must adhere strictly to conditions outlined in the official regulatory labeling to ensure product stability and safety.

---

Required Storage Conditions

• Temperature: The medicine must be stored at a temperature not exceeding 25 C or, in some cases, below 30 C.
• Protection: The product must be protected from light and stored in the original package with the cap immediately replaced after use.
• Child Safety: The medicine must be kept out of the sight and reach of children.
• Stability: Once opened, the product should be discarded after 28 days (or 60 days, as specified by the label) and must not be used after the expiration date.

Disposal Instructions

Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.